Literature DB >> 7459836

Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice.

H D Soule, C M McGrath.   

Abstract

A clone of MCF-7 (MCF-7ED), a cell in continuous in vitro cultivation derived from an estrogen-responsive human breast carcinoma, requires estrogen supplementation for progressive exponential (double time: 50--85 h) tumor growth in the mammary fat of athymic mice. The plasma concentration of estradiol which stimulated exponential growth of MCF-7ED corresponded to physiologic premenopausal levels in women. The tumors were carcinomas with murine and MCF-7ED cells intermixed. MCF-7ED cells could be repurified in subcultures of mixed tumors. Comparative studies of breast and non-breast cell lines showed concordance between the presence of estradiol receptor, sensitivity to the anti-estrogen tamoxifen for growth in vitro, and estradiol dependence for tumorigenic growth in athymic mice. Progesterone alone did not stimulate MCF-7ED growth, but acted synergistically with estrogen. Progesterone's action was to decrease tumor latent period, not to increase final tumor incidence or growth rate. Under estrogen-deficient conditions, condsitions approximating postmenopausal status in women, (10(-10) M in plasma), a dormant state was established between MCF-7ED cells and murine mammary stroma which could be maintained several months. The dormant state could be broken by introduction of estradiol, but not progesterone. This system should be useful for defining host and cancer cell determinants in estrogen-responsive breast cancer growth.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7459836     DOI: 10.1016/0304-3835(80)90042-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  36 in total

1.  Estrogen mitogenic action. III. is phenol red a "red herring"?

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

Review 2.  Targeted functional imaging in breast cancer.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03       Impact factor: 9.236

3.  The human breast and the ancestral reproductive cycle : A preliminary inquiry into breast cancer etiology.

Authors:  K Coe; L B Steadman
Journal:  Hum Nat       Date:  1995-09

4.  c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Authors:  O W Prall; E M Rogan; E A Musgrove; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

5.  The nuclear orphan receptors COUP-TF and ARP-1 positively regulate the trout estrogen receptor gene through enhancing autoregulation.

Authors:  G Lazennec; L Kern; Y Valotaire; G Salbert
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 6.  Long-term adjuvant tamoxifen therapy for breast cancer.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

7.  Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.

Authors:  J S Foster; D C Henley; A Bukovsky; P Seth; J Wimalasena
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

8.  Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells.

Authors:  Xinguo Jiang; Nicole M Patterson; Yan Ling; Jianwei Xie; William G Helferich; David J Shapiro
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

Review 9.  Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.

Authors:  O W Petersen; L Rønnov-Jessen; V M Weaver; M J Bissell
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

10.  Inhibition of postconfluent focus production in cultures of MCF-7 human breast cancer cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  J F Gierthy; D W Lincoln
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.